WO2000005209A1 - GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY - Google Patents
GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY Download PDFInfo
- Publication number
- WO2000005209A1 WO2000005209A1 PCT/CN1998/000133 CN9800133W WO0005209A1 WO 2000005209 A1 WO2000005209 A1 WO 2000005209A1 CN 9800133 W CN9800133 W CN 9800133W WO 0005209 A1 WO0005209 A1 WO 0005209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- solution
- ethanol
- calcium
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- a Vanilloid type ⁇ -blocker has a guaiacyl propanolamine ring, while the previously synthesized Fannil is a derivative of vanillin propanolamine in a series Has been shown to have ⁇ -adrenergic receptor blocking activity.
- the present invention attempts to modify the structure by using Fannile as the basic core, mainly by modifying the fourth fluorene group of Fannile, and introducing a diargyridine ring having vasodilator effect.
- the present invention also uses various pharmacological experiments to confirm that dihydropyridine derivatives having a guaiac propionyl amine and a phenyl propargyl amine structure have a sustained decrease in blood pressure and compete with ⁇ - Adrenaline receptors and calcium ion antagonists, the resulting vasorelaxant effect, calcium ion channel blocking and ⁇ -adrenergic receptor blocking and other activities.
- the present invention further confirms that the dihydropyridine derivatives having guaiaminol propanolamine and benzylaminopropanolamine structures are used as main components, and necessary excipients are added to make various pharmaceutical compositions, which have medicinal effects.
- Control group 2 10 ⁇ M ICI 118, 551. 10 ' 9 M ICI 118 4. 10 8 M ICF 118, 551 Figure 10 Tracheal relaxation effect of the compound of the present invention
- Control group 2.1 T 8 M ICF 118, 551 Figure 11 Receptor binding of compounds of the invention
- Control group 2.
- Control group 50mM potassium chloride
- Control group 2. ⁇ Bay K 8644
- the present invention relates to a dihydropyridine derivative having a guaiacoxypropanolamine and a phenylaminopropanolamine structure, that is, a compound having a main structure of formula I, wherein R is selected from the following four
- R! Can be arbitrarily selected from one of halogen (X), nitrogen gas (N0 2 ), saturated 1-6 carbon straight chain alkyl, unsaturated 1-6 carbon straight chain alkyl.
- R 2 may be arbitrarily selected from hydrogen (H), methyl
- R 3 and R 4 may be arbitrarily selected from one of saturated 1 to 6 carbon linear alkyl group and unsaturated 1 to 6 carbon straight alkyl group;
- R 5 may be arbitrarily selected from hydroxyl group, saturated 1 to 6 carbon straight chain group Alkyl, one of unsaturated 1-6 carbon straight-chain alkyl groups.
- diargyridine derivatives having guaiacoxypropanolamine and phenoxypropanolamine as the main structure of formula I can be roughly divided into four methods. Structure of some compounds.
- purified compound 3 can be obtained in the same step.
- Purified compound 2 can be obtained by the above method.
- purified compound 5 When n-butylamine is used for the amination reaction, purified compound 5 can be obtained in the same step.
- the use of 2-methoxy-1 -aminoethylamino group can lead to purified compound 6 in the same procedure.
- 2-methoxy-l-ethyl ethylaminobenzene As for the preparation method of 2-methoxy-l-ethyl ethylaminobenzene, the following methods can be adopted; After heating 2-methyl-phenylbenzene and dibromoethane, sodium argon is added, and the heating reaction is continued. It was concentrated under reduced pressure and crystallized to obtain 2-methylamino-1-ethylethylbromobenzene.
- the compound of the present invention may be added with various excipients, carriers, or diluents and pharmaceutically acceptable acid addition salts to form a medicinal composition when necessary.
- a preparation may be a solid dosage form, a liquid dosage form for oral administration, rectal administration, or an injection form for parenteral use, or an ointment form directly applied to the affected area.
- Such a solid dosage form is prepared according to a well-known preparation method and may be added with a dispersant such as starch, sodium carboxymethyl cellulose, a binder such as ethanol, glycerin, or magnesium stearate, ginose, and the like. It can also be made into lozenges or filled into capsules or made into solid preparations such as suppositories.
- the aqueous solution and salt solution of the compound of the present invention can be adjusted to pH to a proper level by using phosphate buffers, and additives, emulsifiers can be added to make injections or other liquids.
- the compound of the present invention or a pharmaceutically acceptable acid addition salt can be mixed with various bases, and it can also be prepared into an ointment formulation according to a known preparation method.
- the pharmaceutical composition prepared with the compound of the present invention as the main component can be applied to mammals to produce the main component.
- the general dosage can be adjusted according to the symptoms, usually 50 to 300 mg per person, 3 times a day.
- the compounds of the present invention can be confirmed by the following pharmacological experiments whether they have beta receptor and calcium ion antagonistic activity, selectivity to beta-adrenergic receptors, and whether they have intrinsic mimetics.
- a male rat (Wistar strain) weighing 200-300 g was selected, and anesthesia was performed by intraperitoneal anesthesia with wrong barbital sodium, and a tracheotomy was performed, and a catheter was inserted to maintain smooth breathing.
- the left femoral vein was intubated with a polyethylene tube to facilitate drug administration; and a three-way piston was used, one end of which was connected to a syringe containing an injection drug; the other end was connected to a syringe containing a normal saline solution, which could Immediately inject some saline to prevent drug retention in the polyethylene tube and affect the accuracy of the experiment.
- the left femoral artery was also intubated with a polyethylene tube.
- a three-way piston was also used.
- One end was connected to a heparin solution. When a plug was found in the polyethylene tube, it could be used to unblock the tubing.
- the other end was connected to a disposable diaphragm dome (Disposable Diaphragm Dome Tal019), and then connected to the transducer and recorded the systemic arterial pressure, mean arterial pressure and heart rate by a recorder through an amplifier, in this way, the effect of the drug on blood pressure and heartbeat of the rat can be evaluated.
- Rats were administered different doses of Compound 1, such as 0.1, 0.25.
- rats in other groups received 1.0 mg / kg of compound 2, 3, 4, 5, 6, 7, 8, and 9 respectively through the femoral vein, and then compared the differences in their heartbeat and blood pressure effects.
- Rats weighing 200-300g were selected, and the carotid arteries were cut and bleeded after sacrifice. The entire heart was quickly removed and placed at room temperature (20-25 ° C). The physiology of the mixed gas (95% 0 2 + 5% C0 2 ) In saline (Kreb's) solution, the left and right atria were separated. Take the spontaneously beating right atrium, clamp both ends with a frog heart clamp, fix one end to the bottom, place it in a tissue bath with 10 ml of physiological saline solution, and maintain the temperature at 37 ° C.
- L-isoproterenol concentration starts from 1 X 10 10 M, and its concentration is increased by 0.5 log, giving a total of six concentrations Cumulative dosing interval is to give the next concentration when the previous concentration reaches its maximum effect, the time interval is about 3 to 5 minutes, and its EC 5 o value can be obtained.
- the slope of compound 1 can be used to obtain the ⁇ 2 values.
- n slope value DR: EC 50 of the experimental group divided by EC S0 of the control group
- Rat right atrium was equilibrated in saline (Kreb's) solution for at least 60 minutes, When the rate of autonomic beats reached a steady state, 3.0, 6.0, and 9.0 mM of different concentrations of calcium chloride were cumulatively administered, and the rate of autonomic beats in the right atrium was observed. Then the right atrium and then washed several times with saline solution, re-equilibrate for at least 60 minutes, administered 10 ⁇ 7, 10_ 6, 1 ( ⁇ 5 ⁇ varying concentrations of compound 1, 30 minutes after administration of different concentrations of 3.0 accumulated again, 6.0 and 9.0 mM calcium chloride were used to observe changes in the right atrial autonomic beat rate. Compare the effect of calcium chloride on the right atrial autonomic beat rate in the presence or absence of Compound 1.
- the left atrium which does not spontaneously beat, was isolated from a rat right atrium experiment. Under the same conditions, the left atrium was stimulated with a square wave with a wave width lmses slightly larger than the threshold voltage of about 1 volt and caused a contractile response. Stimulation frequency is 1Hz, rest tension is 0.5g. After 60 minutes of equilibration, perform the following experiments:
- the cumulative administered L - isoproterenol may increase the force of contraction;
- 10- 7, 10 '6, 1 ⁇ 5 ⁇ concentration of compound 4 It can competitively antagonize the cardiac contractility of L-isoproterenol, and the cumulative concentration response curve of L-isoproterenol shows a dose-dependent parallel shift from left to right.
- Beta Type 2 Receptor Selectivity Beta Type 2 Receptor Selectivity:
- ⁇ type The selectivity ratio of ⁇ 2 type receptors is obtained by the difference between the average ⁇ 2 value of the right atrium and the trachea and the negative logarithm. This is based on Baird, RC et al., J. Pharm. 1972 (J. Pharm. Pharmacol) Vol. 24, pp. 880-885.
- the effect of Compound 1 in the right atrium is 1.32 times that of the trachea, vanidilol's effect in the right atrium is 0.98 times that of the trachea, and propranolol's effect in the right atrium is 1.7 times stronger than that of the trachea. It is shown that compound 1 is not selective for ⁇ -type receptors, like vanidel and propranolol.
- guinea pigs weighing 350 to 500 grams were selected. Hourly intraperitoneal injection of 5 mg / kg reserpine to empty the endogenous catecholamines. The guinea pigs were sacrificed before the experiment, and then the trachea was quickly removed and the melons were cultured in a physiological saline (Kreb's) solution at room temperature of about 22 to 25 ° C, which had been ventilated with a mixture of gas (95% 0 2 + 5% C0 2 ).
- Kreb's physiological saline
- reserpine pretreatment for guinea pig tracheal administration cumulative 10- 1Q ⁇ 3 X 10 6 ML - isoproterenol or 10- 10 ⁇ 3 X 10- 6 M where Ni Lonsdale, 10-10 ⁇ 3 X 10 6 M nifedipine and 10-1Q ⁇ 3 X 10 6 compound 1 can produce dose-dependent tracheal relaxation.
- the thoracic aorta was quickly removed, and placed in ice-cold saline (Kreb's) solution to remove the fatty connective tissue around the blood vessel wall, and the thoracic aorta was cut to about A 5mm long ring, with two "hi" shaped platinum wires passing up and down through the thoracic aorta ring, and then placed the thoracic aorta at 10 liters, 37 times and open (95% 0 2 + 5 % CO z ) One end is fixed to the bottom of the tissue groove, and the other end is connected to a force transducer to record its isometric contraction via a recorder. The specimen was given 1 gram of tension, and the following experiment was performed after 60 minutes of equilibration.
- Kreb's ice-cold saline
- the volume of ice-cold trimethylolaminomethane buffer solution was homogenized with a Polytron homogenizer for 15 seconds each time, crushed 3 to 4 times, the homogenate was filtered under pressure with gauze, and the filtrate was centrifuged for 12 minutes (700g), The supernatant was then centrifuged for 12 minutes (10,000 g), and the second supernatant was centrifuged for another 15 minutes (29,000 g); the resulting precipitate was resuspended in a minimum volume of trimethylolaminomethane ( Tris) buffer solution, followed by the method of Brodford (1976), using bovine serum albumin (BSA) as a standard, the protein content of the membrane was determined by a protein analysis dye, and then diluted with a trimethylolaminomethane buffer solution The protein concentration is maintained at 100 ⁇ l containing 200 to 250 ⁇ .
- BSA bovine serum albumin
- ImM magnesium chloride ImM magnesium chloride
- Petrus et al. (1988) and Muzzin et al. (1974) modified the method to take 100 ⁇ 1 membrane, 50 ⁇ 1 [ 3 H] CGP-12177, 50 ⁇ 1 test compounds at different concentrations; propranolol, compound 1, Fan Ni Dyer, make the final volume of 250 ⁇ 1, shake at 25 ° C, and react for 60 minutes.
- Tris-HCl buffer solution 200 ⁇ 1 membrane, 100 ⁇ l of different concentrations of compound 1, nifedipine, van der Niel and other test compounds to make the final volume of 500 ⁇ 1, shake at 25, react in the dark for 60 minutes, then use Filter (Millipore filter device) and filter tube (Whatman GF / C glass fiber) pressurized and quickly filtered, and then 4 l of ice-cold 50mM Tris-Hydroxymethylmethane-hydrochloric acid (Tris-HCl), O.lmM EDTA (pH 7.7) Rinse 4 times, dry the filter paper with cell membrane in a 70 ° C drying oven for 1 hour, add 4 ml of liquid scintillation counting solution, and use a counter (Bechman LS6500 rackbet liquid scintillation counter) to determine the intensity of radioactivity.
- Tris-HCl Tris-Hydroxymethylmethane-hydrochloric acid
- the concentration of free calcium ions in the cells is determined using a fluorescent display agent.
- fluo-mae fluorescent display agent fluo 3-AM
- the computer can convert the fluorescence image into a pseudogray image according to its strength. Scan for 125 seconds after adding 50 mM potassium chloride.
- Bay K 8644 ( 10 ⁇ ) calcium channel activators replace the previous potassium chloride, the same procedure with different concentrations (10- 8, 10 "7, 10- 6 ⁇ ) compound 1 was observed Bay ⁇ 8644 (10m) of intracellular calcium Antagonism with increasing concentration.
- Compound 1 binds to beta receptor 11 and 13, to different concentrations of 0.003 ⁇ 80nM [3 H] CGP - 12177 as a dose-related receptor binding studies, show a [3 H] CGP 12177 binding to rat ventricle, dirty film may arsine
- the Scatchard (1949) analysis method was used to determine the receptor affinity and the number of binding sites.
- the equilibrium dissociation constants of the ventricles and lung membranes were obtained ( Kd) is 0 ⁇ 16 ⁇ 0 ⁇ 03; 1.75 ⁇ 0.50 ( ⁇ ); the maximum binding density of the receptor
- the competition curve of calcium ion blockers in the calcium cortex membrane of rat cerebral cortex is shown in Table 3.
- the pki value is shown in Table 3.
- the calcium blocker inhibitor [ 3 H] Binding of calcium ion receptors, the order of their pharmacological strength is nifedipine> compound of the compounds of the present invention, heartbeat, blood pressure [ 3 H] Nitrandipine [ 3 H] CGP-12177 [ 3 H] CGP-12177
- KC1 and 1 ⁇ m BayK8644 plus fluoro-mae fluorescent display agent (fluo3-AM)
- fluoro3-AM fluoro-mae fluorescent display agent
- N— [4 — (2, 3 -cycloaminopropoxy)-3 -methylamino]-1 -benzidine and tert-butylamine dissolve in 100ml of absolute ethanol, at a slight temperature Amidation reaction is carried out, and after stirring overnight, solid white crystals can be obtained. After recrystallization from methanol, a purified compound N- ⁇ 4- (2 -hydroxy-3-(tert-butylamino)) can be obtained. (Propoxy) -3-methylamino ⁇ -1-benzaldehyde.
- compound 1 is (4- ⁇ 4- [2 -hydroxy-3-(t-butylamino) propanyl] -3 -methylamino ⁇ phenyl)-2, 6 -di Methyl mono-3,5-dimethylmethyl-1,4-diargyridine.
- Example 2 Synthesis of Compound 2 Heat 0.2 mol of 2-Methoxyphenol and 0.4 mol of dibromoethane in a three-necked flask to a boil, stir with a stir bar for 30 minutes, add 125 ml of 1.6N sodium argon, and then heat Stir layers. After heating overnight, the reaction was determined to be complete using a thin layer of ⁇ , and the organic layer was repeatedly extracted with chloroform.
- the structural formula of the obtained compound 2 was C 3 ( , H 38 0 9 N 2) , and the molecular weight obtained after analysis by a mass spectrometer was 570.
- compound 2 is 4- ⁇ - ⁇ 4- ⁇ 2 -hydroxy-3-(2 -methoxy- 1 -fluorenylethylbenzyl) propanyl]-3 —Methylamino ⁇ phenyl ⁇ -2,6-dimethyl-3,5-dimethylmethyl-1,4-dihydropyridine.
- the structural formula of the obtained compound 3 is C 32 H 42 0 9 N 2 , and the molecular weight obtained after fractionation by a mass spectrometer is 598.
- compound 3 was found to be 4-[[N-[(2 -hydroxy-3-(2-methoxy-1 -oxoethylaminobenzyl) propanyl j-3 -methoxy Group) benzyl) — 2, 6-dimethyl-3, 5-diethylethyl — 1, 4-dihydropyridine.
- the structural formula of the obtained compound 4 was C 26 H 37 0 6 N 2 C1, and the molecular weight was 508.5 after being decanted by a mass spectrometer. 'HN IKCDCl ⁇ US-U s',
- compound 4 is 4- ⁇ 2-[2-hydroxy-3-(tert-butylamino) propanyl]-5 -chloro ⁇ benzyl ⁇ -2, 6 -dimethyl —3,5-diethylethyl—1,4-dihydropyridine.
- the structural formula of the obtained compound 5 was C 26 I-I 37 0 6 N 2 C1, and the molecular weight obtained after fractionation by a mass spectrometer was 508.5.
- compound 5 is 4- ⁇ 2-[2-hydroxy-3-(n-butylamino) propoxy]-5 chloro ⁇ phenyl ⁇ — 2, 6 -dimethyl — 3,5 -diethyl- 1,4-dihydrogen.
- the structural formula of the obtained compound 6 is C 31 H 3 () 0 8 N 2 C1, and the molecular weight obtained after analysis by a mass spectrometer is 602.5.
- compound 6 is 4- ⁇ 2-[2 -hydroxy-3 -(2 -methylamino-1 -oxoethylaminophenyl) propanyl]-5 -chloro ⁇ phenyl ⁇ -2, 6 —dimethyl-3, 5 — diethylethyl — 1, 4-Dihydropyridine.
- the structural formula of the obtained compound 7 was C 31 H 3 () 0 8 N 2 C1, and the molecular weight was 602.5 after being decanted by a mass spectrometer.
- compound 7 is 4- ⁇ N- ⁇ 4-[2-hydroxy-3-(2-methoxy-1 -aminoethylphenyl)) Propionyl]-3 -chloro ⁇ phenyl ⁇ -2,6-dimethyl-3,5-diethylethyl-1,4-dihydropyridine.
- the structural formula of the obtained compound 8 is C 26 H 37 0 8 N 3 , and the molecular weight obtained after fractionation by a mass spectrometer is 519. 'H-NMRCCDCl ⁇ lM-l. ⁇ (S, 9H, 3
- compound 8 is 4-U2-[2-hydroxy-3-(n-butylamino) propanyl] -5 -nitro] phenyl ⁇ -2, 6 -dimethyl- 3, -diethylethyl-1,4-dihydropyridine.
- the structural formula of the obtained compound 9 was C 31 H 35 O 10 N 3 , and the molecular weight was 609 after being decanted by a mass spectrometer.
- the structural formula of the obtained compound 10 was C 32 H 42 0 9 N 2 , and the molecular weight obtained after fractionation by a mass spectrometer was 598.
- Compound 10 is 4- ⁇ N — [3-[2-monohydroxy — 3 — (2-methylamino-1 -oxoethylaminophenyl) propanyl]-4 -methoxy] phenyl ⁇ ⁇ -2, 6-dimethyl-3, 5-diethylethyl-1, 4-dihydropyridine.
- the present invention relates to a dihydropyridine derivative having a guaiamidopropanolamine and a phenylfluorenylpropanolamine structure, that is, a compound having a main structure of formula I, wherein each substituent is as described in the specification. It has continuous blood pressure drop, competes for ⁇ -adrenergic receptor and calcium ion antagonist activity, produces vasorelaxation, block calcium channels, and ⁇ -adrenergic blocker activity.
- R 2 can be arbitrarily selected from the group consisting of halogen, nitrogen gas, nitrogen, saturated 1-6 carbon straight-chain alkyl group, and unsaturated 1-6 carbon straight-chain alkyl group, and R 2 can be arbitrarily selected from hydrogen, methyl,
- R 3 and R 4 may be any one of a saturated 1 to 6 carbon straight chain alkyl group and an unsaturated 1 to 6 straight alkyl group
- R 5 may be arbitrarily selected from a hydroxyl group and a saturated 1 to 6 carbon chain Alkyl, one of unsaturated 1-6 broken straight alkyl.
- a pharmaceutical composition having competitive ⁇ -adrenergic receptor activity comprising a compound of formula I as a main component, and adding various excipients or diluents as necessary.
- a pharmaceutical composition having a calcium ion channel blocker activity comprising a compound of formula I as a main component, and adding various excipients or diluents as necessary.
- a pharmaceutical composition having a continuous blood pressure lowering activity comprising a compound of formula I as a main component, and adding various excipients or diluents as necessary.
- a pharmaceutical composition having vasorelaxant action activity comprising a compound of formula I as a main component, and adding various excipients or diluents as necessary.
- a method for producing a dihydropyridine derivative having a guaiacyl propanolamine and a benzyl propanolamine structure comprising dissolving a substituted benzyl ⁇ in a sodium hydroxide ethanol solution and adding epichlorohydrin After the alcohol reaction, an amination reaction is performed, and the ester compound, ethanol, and concentrated ammonia water are added for reflux, and the solution is concentrated under reduced pressure directly to remove ethanol. The remaining solution is added to a saturated salt breaking solution, extracted with chloroform, and then separated and purified by a column. , Repeated recrystallization to obtain the compound. 7. The production method according to claim 6, wherein the butylamino group and the 2-methylamino-1-gasethylaminobenzene are optionally used for the amination reaction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN1998/000133 WO2000005209A1 (en) | 1998-07-23 | 1998-07-23 | GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY |
AU84300/98A AU8430098A (en) | 1998-07-23 | 1998-07-23 | Guaiacoxypropanolamines with alpha/beta-adrenergic blocking activity |
EP98934740A EP1108710A4 (en) | 1998-07-23 | 1998-07-23 | GUAIACOXYPROPANOLAMINE WITH ALPHA / BETA ADRENERGIC INHIBIT ACTIVITY |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN1998/000133 WO2000005209A1 (en) | 1998-07-23 | 1998-07-23 | GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000005209A1 true WO2000005209A1 (en) | 2000-02-03 |
Family
ID=4575068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN1998/000133 WO2000005209A1 (en) | 1998-07-23 | 1998-07-23 | GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1108710A4 (zh) |
AU (1) | AU8430098A (zh) |
WO (1) | WO2000005209A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016885A2 (en) * | 2003-08-14 | 2005-02-24 | Artesian Therapeutics, Inc. | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
US9974759B2 (en) | 2013-05-31 | 2018-05-22 | Indiana University Research And Technology Corporation | Beta 2 adrenoceptor antagonists for treating orthostatic hypotension |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2405658A1 (de) * | 1973-02-13 | 1974-08-29 | Science Union & Cie | 4-aryl-1,4-dihydropyridine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US3923818A (en) * | 1972-06-10 | 1975-12-02 | Bayer Ag | 1,4-Dihydropyridines |
US3932646A (en) * | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate |
EP0007293A1 (en) * | 1978-06-30 | 1980-01-23 | Aktiebolaget Hässle | 2,6-Dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ester-5-ethyl ester having hypotensive properties, process for its preparation and pharmaceutical preparations containing it |
EP0039892A1 (de) * | 1980-05-09 | 1981-11-18 | Ciba-Geigy Ag | Substituierte Phenyläther |
US4478834A (en) * | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
US4505920A (en) * | 1983-03-03 | 1985-03-19 | Usv Pharmaceutical Corporation | Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use |
JPS6056956A (ja) * | 1983-09-08 | 1985-04-02 | Shoichiro Ozaki | 1,4−ジヒドロピリジン誘導体及びその製法 |
EP0163238A2 (en) * | 1984-05-29 | 1985-12-04 | Merck & Co. Inc. | Substituted and bridged pyridines useful as pharmaceutical agents |
WO1992002503A1 (en) * | 1990-08-02 | 1992-02-20 | Cedona Pharmaceuticals Bv | Novel 1,4-dihydropyridine derivatives |
EP0500426A1 (fr) * | 1991-02-20 | 1992-08-26 | Instituto de Investigacion Y Desarrollo Quimico-Biologico S.A. | Dérivés de 2,6-diméthyl-4-(4'-hydroxy-3',5'-di-t-butylphényl)-1,4-dihydropyridine, leur procédé de préparation et leur utilisation comme capteurs de radicaux libres |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2117573C3 (de) * | 1971-04-10 | 1978-07-27 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von unsymmetrischen l,4-Dihydropyridin-3,5dicarbonsäureestern, sowie ihre Verwendung als Arzneimittel |
US3907808A (en) * | 1971-05-17 | 1975-09-23 | Sterling Drug Inc | 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives |
GB1430961A (en) * | 1972-01-22 | 1976-04-07 | Yamanouchi Pharma Co Ltd | 1-substituted-1,4-dihyddrypyridine derivatives |
US4548941A (en) * | 1984-07-30 | 1985-10-22 | Merck & Co., Inc. | 1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers |
GB8503425D0 (en) * | 1985-02-11 | 1985-03-13 | Ici Plc | Alkanolamine derivatives |
WO1997027177A2 (en) * | 1996-01-29 | 1997-07-31 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
-
1998
- 1998-07-23 EP EP98934740A patent/EP1108710A4/en not_active Withdrawn
- 1998-07-23 AU AU84300/98A patent/AU8430098A/en not_active Abandoned
- 1998-07-23 WO PCT/CN1998/000133 patent/WO2000005209A1/zh not_active Application Discontinuation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932646A (en) * | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate |
US3923818A (en) * | 1972-06-10 | 1975-12-02 | Bayer Ag | 1,4-Dihydropyridines |
DE2405658A1 (de) * | 1973-02-13 | 1974-08-29 | Science Union & Cie | 4-aryl-1,4-dihydropyridine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
EP0007293A1 (en) * | 1978-06-30 | 1980-01-23 | Aktiebolaget Hässle | 2,6-Dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ester-5-ethyl ester having hypotensive properties, process for its preparation and pharmaceutical preparations containing it |
EP0039892A1 (de) * | 1980-05-09 | 1981-11-18 | Ciba-Geigy Ag | Substituierte Phenyläther |
US4478834A (en) * | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
US4505920A (en) * | 1983-03-03 | 1985-03-19 | Usv Pharmaceutical Corporation | Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use |
JPS6056956A (ja) * | 1983-09-08 | 1985-04-02 | Shoichiro Ozaki | 1,4−ジヒドロピリジン誘導体及びその製法 |
EP0163238A2 (en) * | 1984-05-29 | 1985-12-04 | Merck & Co. Inc. | Substituted and bridged pyridines useful as pharmaceutical agents |
WO1992002503A1 (en) * | 1990-08-02 | 1992-02-20 | Cedona Pharmaceuticals Bv | Novel 1,4-dihydropyridine derivatives |
EP0500426A1 (fr) * | 1991-02-20 | 1992-08-26 | Instituto de Investigacion Y Desarrollo Quimico-Biologico S.A. | Dérivés de 2,6-diméthyl-4-(4'-hydroxy-3',5'-di-t-butylphényl)-1,4-dihydropyridine, leur procédé de préparation et leur utilisation comme capteurs de radicaux libres |
Non-Patent Citations (1)
Title |
---|
See also references of EP1108710A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1108710A1 (en) | 2001-06-20 |
EP1108710A4 (en) | 2001-11-21 |
AU8430098A (en) | 2000-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4854970B2 (ja) | 療法において有用なトロパン誘導体 | |
RU2277094C2 (ru) | Производные n-гетероциклических соединений, фармацевтическая композиция на их основе и способ лечения | |
FI88504B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-benzyl-1-(2h)-ftalazinonderivat | |
JPH10511695A (ja) | N−(アロイル)グリシンヒドロキサム酸誘導体および関連化合物 | |
CA2378499A1 (en) | Cyclic amine ccr3 antagonists | |
CN106132945B (zh) | 酰胺化合物 | |
TW200925154A (en) | Phenylacetic acid compound | |
JPH11507339A (ja) | アルファ1aアドレナリンレセプターアンタゴニスト | |
NO174959B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive N-aminobutyl-N-fenyl-arylamidderivater | |
TW201026664A (en) | Ethynylindole compounds | |
SU1486062A3 (ru) | Способ получения ν-алкилированной дигидролизергиновой кислоты | |
WO2000005209A1 (en) | GUAIACOXYPROPANOLAMINES WITH α/β-ADRENERGIC BLOCKING ACTIVITY | |
JP4778449B2 (ja) | Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 | |
HU194879B (en) | Process for producing 1,6-naphtiridine derivatives and pharmaceutical compositions containing them | |
KR101406736B1 (ko) | 아고멜라틴 히드로브로마이드 히드레이트 및 이의 제법 | |
JPS62174050A (ja) | 3−アミノカルボニル−1,4−ジヒドロピリジン−5−カルボン酸誘導体、その製法および医薬組成物 | |
HU201538B (en) | Process for producing 3-hydroxy-2-(4-methoxyphenyl)-5-brackets open 2-(methylamino)-ethyl brackets closed-2,3-dihydro-5h-1,5-benzothiazepin-4-one derivatives and pharmaceutical compositions comprising same | |
JP2002520408A (ja) | ヒトα1dアドレナリン受容体に特異的な化合物およびその使用 | |
WO2015046404A1 (ja) | 肺高血圧症の治療剤又は予防剤 | |
TW580495B (en) | An 1,4-dihydropiridine derivative chemically with guaiacoxypropanolamine based phenoxypropanolamine moiety | |
JP4223237B2 (ja) | 3−フェニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物、これを含有する医薬品、その使用及びその製法 | |
TWI320038B (en) | An 1,4-dihydropiridine derivatives pharmacologically with adrenoceptor and calcium channel blocking activities | |
AU619049B2 (en) | New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it | |
JPH05504345A (ja) | 新規ジヒドロピリジン | |
JP2007186422A (ja) | アリールスルフィド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998934740 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998934740 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998934740 Country of ref document: EP |